Reversal of vecuronium induced residual neuromuscular block using sugammadex: a prospective, dobule-blind, randomized, controlled, dosefinding study

Trial Profile

Reversal of vecuronium induced residual neuromuscular block using sugammadex: a prospective, dobule-blind, randomized, controlled, dosefinding study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Sugammadex (Primary) ; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Results published in the Anesthesiology
    • 09 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top